Vyxeos Injection Improves Overall Survival in Phase III Acute Myeloid Leukemia Trial 

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A phase III trial of Vyxeos Liposome for Injection demonstrated statistically significant improvements in overall survival in patients with high-risk secondary acute myeloid leukemia.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login